Skip to main content

Table 1 Baseline characteristics of the ITT population, by treatment arm and age. Reported as n (%) unless otherwise indicated

From: EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer

Characteristics Arm A, 100 mg/m2 Arm B, 125 mg/m2
Overall (N = 79) Patients aged 75+ (N = 33) Overall (N = 79) Patients aged 75+ (N = 33)
Median age in years (range) 72 (65–84) 80 (75–84) 73 (65–88) 77 (75–88)
Age
 65–69 28 (35) 21 (27)
 75+ 33 (42) 33 (100) 33 (42) 33 (100)
ECOG PS
 0 51 (65) 20 (61) 43 (54) 19 (58)
 1 19 (24) 9 (27) 32 (41) 13 (40)
 2 9 (11) 4 (12) 4 (5) 1 (3)
ADL scores
 Impaired [range] 14 (18) [5/6–4/6] 6 (18) [5/6–5/6] 20 (25) [5/6–1/6] 8 (24) [5/6–1/6]
 Missing data 2 (2) 2 (2) 0 0
IADL scores
 Impaired [range] 20 (25) [7/8–2/8] 9 (3) [7/8–4/8] 20 (25) [7/8–2/8] 8 (24) [7/8–3/8]
 Missing data 2 (2) 1 (3) 0 0
Comorbidities
 Any grades 3–4 8 (10) 6 (18) 10 (13) 3 (9)
 Diabetes mellitus 9 (11) 6 (18) 11 (14) 4 (12)
HR status
 ER− and PgR− 9 (11) 5 (15) 8 (10) 4 (12)
 ER+ and/or PgR+ 68 (86) 28 (85) 67 (85) 28 (85)
 Missing data 2 (3) 0 4 (5) 1 (3)
HER2 status
 Positive 2 (3) 1 (3) 0 0
 Missing data 5 (6) 2 (6) 10 (13) 4 (12)
Prior taxane use 11 (14) 3 (9) 10 (13) 1 (3)
Measurable disease 60 (76) 22 (67) 65 (82) 28 (85)
Visceral disease 56 (71) 22 (67) 55 (69) 25 (76)
  1. ADL activities of daily living, ECOG PS Eastern Cooperative Oncology Group Performance Status, IADL instrumental ADL, + positive, negative